Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Molecular mechanisms of IL-33–mediated stromal interactions in cancer metastasis
Patrik Andersson, … , Qi Li, Yihai Cao
Patrik Andersson, … , Qi Li, Yihai Cao
Published October 18, 2018
Citation Information: JCI Insight. 2018;3(20):e122375. https://doi.org/10.1172/jci.insight.122375.
View: Text | PDF
Research Article Cell biology Oncology

Molecular mechanisms of IL-33–mediated stromal interactions in cancer metastasis

  • Text
  • PDF
Abstract

Molecular mechanisms underlying the cancer stroma in metastasis need further exploration. Here, we discovered that cancer-associated fibroblasts (CAFs) produced high levels of IL-33 that acted on tumor-associated macrophages (TAMs), causing them to undergo the M1 to M2 transition. Genomic profiling of metastasis-related genes in the IL-33–stimulated TAMs showed a >200-fold increase of MMP9. Signaling analysis demonstrated the IL-33-ST2-NF-κB-MMP9-laminin pathway that governed tumor stroma–mediated metastasis. In mouse and human fibroblast-rich pancreatic cancers, genetic deletion of IL-33, ST2, or MMP9 markedly blocked metastasis. Pharmacological inhibition of NF-κB and MMP9 also blocked cancer metastasis. Deletion of IL-33, ST2, or MMP9 restored laminin, a key basement membrane component associated with tumor microvessels. Together, our data provide mechanistic insights on the IL-33-NF-κB-MMP9-laminin axis that mediates the CAF-TAM–committed cancer metastasis. Thus, targeting the CAF-TAM-vessel axis provides an outstanding therapeutic opportunity for cancer treatment.

Authors

Patrik Andersson, Yunlong Yang, Kayoko Hosaka, Yin Zhang, Carina Fischer, Harald Braun, Shuzhen Liu, Guohua Yu, Shihai Liu, Rudi Beyaert, Mayland Chang, Qi Li, Yihai Cao

×

Figure 2

IL-33 upregulates MMP9 in macrophages through ST2 activation.

Options: View larger image (or click on image) Download as PowerPoint
IL-33 upregulates MMP9 in macrophages through ST2 activation.
(A) Heatma...
(A) Heatmap of a subset of cancer metastasis–related genes by genome-wide expression profiling of IL-33–stimulated macrophages (n = 3 samples per group). (B) qPCR quantification of mRNA expression levels of Mmps in IL-33–stimulated macrophages (n = 6 samples per group). (C) Inhibition of Mmp9 mRNA expression of IL-33–stimulated macrophages by a soluble ST2 (IL-33 trap) (n = 6 samples per group). sST2, soluble ST2. (D) ELISA quantification of active MMP9 protein in the conditional medium from IL-33–stimulated macrophages (n = 3 samples per group). (E) qPCR quantification of Mmp9 mRNA levels in F4/80+ cells isolated from Panc02 tumors grown in WT or St2–/– mice (n = 6 samples per group). (F) Detection of MMP9 protease activity by a gelatin-based zymography assay in conditional medium derived from IL-33–stimulated macrophages in the presence or absence of a soluble ST2 (n = 3 samples per group). NT, nontreated. Mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, Student’s t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts